AI assistant
Sending…
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2024
Jun 17, 2024
7082_dirs_2024-06-17_2219eb79-1f73-414d-b5bc-301a7ecfd52c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2024-06-15
Reporting Person: Nisen Perry (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-15 | Ordinary Shares | M | 21108 | — | Acquired | 95683 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-15 | Restricted Share Units | $ | M | 21108 | Disposed | Ordinary Shares (21108) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024.